Current share price for MSB : $1.760 0.035 (1.95%)+
Mesoblast Limited (MSB) is an ASX-listed company and is held by a number of exchange traded funds (ETFs). It is a Company that is engaged in developing allogeneic (off-the-shelf) cellular medicines for the treatment of inflammatory conditions. The therapies from the Company's proprietary mesenchymal lineage cell therapy technology platform respond to inflammation by releasing anti-inflammatory factors that counter and modulate multiple effector arms of the immune system, resulting in reduction of the damaging inflammatory process.
| ASX Code | MSB |
| Website | http://www.mesoblast.com |
| Industry/Sector | Biotechnology |
| Market Cap ($M) | 2,290 |
| MSB Share Price | $1.760 |
| Day High | $1.823 |
| Day Low | $1.760 |
| Last Close | $1.795 |
| MSB Share Price Movement | $0.03 ( 1.95% ) |
As a significant Australian company by market capitalisation, MSB is held across 21 ETFs spanning strategies that include biotechnology exposure . Its weighting in those funds means performance can have an outsized influence - when MSB moves, funds like ISO, SSO, FAIR, VSO and OZXX that hold it can move with it.
For more concentrated exposure, ETFs such as ISO (iShares S&P/ASX Small Ordinaries ETF Index Fund) allocate about 0.6% to MSB , while the average exposure across all 21 ETFs that hold it is around 0.2% .
Last updated: ETF data and holdings as at 17 November 2026
How does holding Mesoblast Limited (MSB) shares directly compare to ETFs that include it?
|
MSB Direct
|
ISO
ASX |
SSO
ASX |
FAIR
ASX |
VSO
ASX |
OZXX
ASX |
|
|---|---|---|---|---|---|---|
| Holdings | 1 company | 220 holdings | 220 holdings | 95 holdings | 204 holdings | 109 holdings |
| MSB Weight | 100% | 0.6% | 0.6% | 0.5% | 0.3% | 0.2% |
| Diversification | Single Stock | Broad | Broad | Broad | Broad | Broad |
| Annual Cost | Brokerage only | 0.55% p.a. | 0.5% p.a. | 0.49% p.a. | 0.3% p.a. | 0.25% p.a. |
| Approx. Yield | 0% | 4.69% | 9.91% | 2.97% | 4.97% | 5.43% |
| Star Ratings | - |
Yields and costs are approximate. ETF yields reflect the fund's dividend distributions, not MSB's direct yield. Annual cost uses each ETF's MER.
How a $10,000 investment in Mesoblast Limited (MSB) one week ago compares with ETFs that hold it.
| Security | Investment type | Current price | 7-day price movement | Dollar change | Value today |
|---|---|---|---|---|---|
| Mesoblast Limited (MSB) | Direct share | $1.760 | -15.38% | -$1,538 | $8,462 |
| iShares S&P/ASX Small Ordinaries ETF Index Fund (ISO) | Equity - Australia Small/Mid Cap | $4.660 | -5.48% | -$548 | $9,452 |
| State Street SPDR S&P/ASX Small Ordinaries ETF (SSO) | Equity - Australia Small/Mid Cap | $13.530 | -4.72% | -$472 | $9,528 |
| BetaShares Australian Sustainability Leaders ETF (FAIR) | Equity - Australia Strategy | $19.480 | -0.81% | -$81 | $9,919 |
| Vanguard MSCI Australian Small Companies Index ETF (VSO) | Equity - Australia Small/Mid Cap | $70.290 | -4.73% | -$473 | $9,527 |
| Global X Australia ex Financials & Resources ETF (OZXX) | Equity - Australia Sectors | $10.360 | -1.52% | -$152 | $9,848 |
Assumes $10,000 invested 7 days ago. Figures are based on price movement only and exclude distributions, fees and brokerage.
21 ETFs hold Mesoblast Limited (MSB).
| ETF | MSB Weight | MER | Yield |
|---|---|---|---|
| iShares S&P/ASX Small Ordinaries ETF Index Fund (ISO) | 0.6% | 0.55% | 4.69% |
| State Street SPDR S&P/ASX Small Ordinaries ETF (SSO) | 0.6% | 0.5% | 9.91% |
| BetaShares Australian Sustainability Leaders ETF (FAIR) | 0.5% | 0.49% | 2.97% |
| Vanguard MSCI Australian Small Companies Index ETF (VSO) | 0.3% | 0.3% | 4.97% |
| Global X Australia ex Financials & Resources ETF (OZXX) | 0.2% | 0.25% | 5.43% |
| Betashares Australian Ex-20 Portfolio Diversifier ETF (EX20) | 0.2% | 0.25% | 2.81% |
| Dimensional Australian Core Equity (Managed Fund) (DACE) | 0.2% | 0.28% | 3.2% |
| Betashares Geared Australian Equity Fund (GEAR) | 0.2% | 2.11% | 1.81% |
| Vanguard Ethically Conscious Australian Shares ETF (VETH) | 0.1% | 0.16% | 2.82% |
| Betashares Managed Risk Australian Share Fund (AUST) | 0.1% | 0.49% | 3.02% |
| Distribution Type | Dividend | Franking | Ex-dividend date | Payment date | Current Price+ | Price 7D Avg | Dividend Yield |
|---|
See all dividends from Mesoblast Limited (MSB) or use our Upcoming Dividends tool to search for dividends across all ASX-listed securities.
| Year to Jun | NPAT | EPS | EPS chg (%) | PER | DPS | Yield (%) | Franking (%) |
|---|---|---|---|---|---|---|---|
| 2028F | C2 | $0.20 | -106.50% | 815.90 | 0.00 | 0.00% | 0.0% |
| 2027F | C2 | -$3.40 | -50.20% | 0.00 | 0.00 | 0.00% | 0.0% |
| 2026A | -$87.79 | -$6.80 | -45.00% | 0.00 | 0.00 | 0.00% | 0.0% |
| Company | Mkt Cap | EPS Growth (%) | P/E (%) | Dividend Yield (%) | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| 2026 A | 2027 F | 2028 F | 2026 A | 2027 F | 2028 F | 2026 A | 2027 F | 2028 F | ||
| CSL Limited (CSL) | $97,186M | 0.7309 | -0.4374 | 0.0602 | 12.5465 | 22.3000 | 21.0343 | 2.10% | 2.11% | 2.18% |
| Clinuvel Pharmaceuticals Limited (CUV) | $383M | -0.0696 | -0.0719 | 0.0242 | 11.3623 | 12.2419 | 11.9528 | 0.66% | 0.66% | 0.66% |
| Mesoblast Limited (MSB) | $2,453M | -0.4501 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 856.8182 | 0.00% | 0.00% | 0.00% |
| PYC Therapeutics Limited (PYC) | $1,763M | -0.3971 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.00% | 0.00% | 0.00% |
| Telix Pharmaceuticals Limited (TLX) | $4,557M | -1.3893 | 0.0000 | -0.5229 | 0.0000 | 156.9754 | 328.9926 | 0.00% | 0.00% | 0.00% |
| Earnings | P/E Ratio | P/B Ratio | P/E Growth | |
|---|---|---|---|---|
| Company | 0.00 | 0.00 | 2.81 | 0.00 |
| Market | 0.64 | 15.60 | 1.43 | 1.28 |
| Sector | 0.74 | 33.00 | 2.24 | 2.76 |
| Name | Position | Start Date |
|---|---|---|
| Professor Silviu Itescu | Chief Executive Officer, Executive Director | 8 Jun 2004 |
| Ms Jane Catherine Bell | Non-Executive Director | 18 Aug 2022 |
| Ms Lynette Elizabeth Cobley | Non-Executive Director | 29 Apr 2025 |
| Dr Gregory George | Non-Executive Director | 24 Feb 2025 |
| Mr Jon Voigtman | Non-Executive Director | 10 Nov 2026 |
| Mr Philip J. Facchina | Non-Executive Director, Non-Executive Chairman | 29 Mar 2021 |
| Date of change | Director | Buy/Sell | Security Type | Qty | Trade Price | Value |
|---|---|---|---|---|---|---|
| 17 Jul 2026 | ITESCU, Silviu | Exercise | Options | 1,885,334 | $1.450 | $2,733,734.000 |
| 17 Jul 2026 | ITESCU, Silviu | Buy | Direct Shares | 1,885,334 | $1.450 | $2,733,734.000 |
| 10 Apr 2026 | GEORGE, Gregory | Buy | Indirect Shares | 7,210,962 | $1.445 | $10,418,591.090 |
See all changes in directors' interest & trades for Mesoblast Limited (MSB) or use our Changes in directors' interest tool to search for changes & trades across all ASX-listed securities.
| Name | Position |
|---|---|
| Niva Sivakumar | Joint Company Secretary |
| Paul Hughes | Joint Company Secretary |
Under ASX rules large investors and investment funds must disclose when they own more than a 5% stake in Mesoblast Limited (MSB). However, you won't necessarily see their names in the company’s annual report, as many trade under nominee names. These shareholders are obliged to provide ongoing substantial notices relating to any change of 1% or more.
| Holding | Name |
|---|---|
| 286,002,539 (22.04%) | Gregory George Patching |
| 80,844,262 (6.23%) | Silviu Itescu |
| 65,660,115 (5.06%) | State Street Corporation and its subsidiaries |
| 64,171,900 (4.95%) | William Gueck |
| Date | Event |
|---|---|
| 11 October 2027 | Report (Annual) |
| 26 August 2027 | Report (Prelim) |
| 26 February 2027 | Report (Interim) |
DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.
Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate,
complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892)
and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and,
if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest.
No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser.
Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.